Experimental drug offers hope for Tough-to-Treat cancers
NCT ID NCT07309770
Summary
This study is testing an experimental drug called Trastuzumab Rezetecan for people with advanced HER2-positive cancers that have stopped responding to standard treatments. The trial will enroll 90 participants with specific rare or hard-to-treat tumors to see if the drug can shrink their cancer and how long the effects last. Patients receive the drug through an IV every three weeks and are closely monitored for tumor response and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY-DRUG CONJUGATES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.